I-Ilumya (tildrakizumab-asmn)

-Delile

• Yini i-Ilumya?
• Ukuvunyelwa kwe-FDA
• Ilumya ejwayelekile
• Izindleko ze-Ilumya
• Usizo lwezezimali nolomshuwalense
• I-Ilumya isebenzisa
• I-Ilumya ye-plaque psoriasis
• Ukusetshenziswa okungavunyelwe
• Isikali se-Ilumya
• Amafomu wezidakamizwa namandla
• Isikali se-plaque psoriasis
• Kuthiwani uma ngiphuthelwa umthamo?
• Ngabe kuzodingeka ngisebenzise lesi sidakamizwa isikhathi eside?
• Imiphumela emibi ye-Ilumya
• Imiphumela emibi ejwayelekile
• Imiphumela emibi kakhulu
• Ukuphendula kwesayithi lokujova
• Uhudo
• Ingozi eyengeziwe yokutheleleka
• Ukusabela komzimba ku-Ilumya
• Ezinye izindlela ze-Ilumya
• Ilumya vs. Tremfya
• Mayelana
• Isebenzisa
• Amafomu wezidakamizwa nokuphathwa
• Imiphumela emibi kanye nezingozi
• Ukusebenza ngempumelelo
• Izindleko
• Ilumya vs. ezinye izidakamizwa
• Ilumya vs. Cosentyx
• Ilumya vs. Humira
• Ilumya vs. Enbrel
• Ilumya vs. methotrexate
• Ukusetshenziswa kwe-Ilumya nezinye izidakamizwa
• Ilumya notshwala
• Ukusebenzisana kwe-Ilumya
• Ilumya nemithi yokugoma ebukhoma
• Ungayithatha kanjani i-Ilumya
• Ngaphambi kokuqala ukwelashwa kwe-Ilumya
• Isikhathi
• Usebenza kanjani u-Ilumya
• Kuthatha isikhathi esingakanani ukusebenza?
• Ilumya nokukhulelwa
• Ilumya nokuncelisa
• Imibuzo ejwayelekile mayelana ne-Ilumya
• Ingabe i-Ilumya yelapha i-plaque psoriasis?
• Bengihlala ngisebenzisa okhilimu be-plaque psoriasis yami. Kungani ngidinga ukuqala ukuthola imijovo?
• Ngizodinga isikhathi esingakanani ukuthatha i-Ilumya?
• Yini umuthi we-biologic?
• Ngabe i-Ilumya isetshenziselwa ukwelapha i-psoriatic arthritis?
• Kungani ngidinga ukuhlolwa i-TB ngaphambi kokuqala ukwelashwa no-Ilumya?
• Yini engingayenza ukuvimbela izifo ngenkathi ngithatha i-Ilumya?
• Isexwayiso se-Ilumya
• Imininingwane yobungcweti ye-Ilumya
• Indlela yokusebenza
• I-Pharmacokinetics ne-metabolism
• Izimo
• Imigomo
• Ukuzilungiselela ngaphambili
• Isitoreji

Yini i-Ilumya?

I-Ilumya (tildrakizumab-asmn) umuthi kadokotela osetshenziswa ukwelapha i-plaque psoriasis elinganiselayo kuya kwelinzima. Inqunyelwe abantu abadala abafanele ukuthola i-systemic therapy (izidakamizwa ezinikezwa ngomjovo noma ezithathwe ngomlomo) noma i-phototherapy (i-light therapy).

I-Ilumya uhlobo lomuthi obizwa ngokuthi yi-monoclonal antibody. I-anti-monoclonal antibody iyiprotheni ekhethekile yesistimu yomzimba eyenzelwe elebhu. Lawa maprotheni akhomba izingxenye ezithile zesistimu yakho yokuzivikela ezifweni. Luhlobo lokwelashwa kwe-biologic (izidakamizwa ezenziwe ngezinto eziphilayo esikhundleni samakhemikhali).

U-Ilumya uza ngesirinji eyodwa egcwaliswe ngomthamo owodwa. Umhlinzeki wezokunakekelwa kwempilo ehhovisi likadokotela wakho uliphatha ngokulijova ngaphansi kwesikhumba sakho (umjovo ongaphansi)

Ngemuva kwemithamo yokuqala emibili, enikezwa amasonto amane ngokuhlukana, u-Ilumya unikezwa njalo emavikini ayi-12.

Ezifundweni zomtholampilo, phakathi kwamaphesenti angama-55 namaphesenti angama-58 abantu abathola i-Ilumya babenezimpawu ezincanyana noma ezisuliwe ze-psoriasis ngemuva kwamasonto ayi-12. Abantu abangaphezu kwababili kwabathathu ababenayo le miphumela bayigcina ngaphezu kwamasonto angama-64.

Ukuvunyelwa kwe-FDA

I-Ilumya yamukelwa yi-Food and Drug Administration (FDA) ngoMashi 2018.

Ilumya ejwayelekile

I-Ilumya itholakala kuphela njengomuthi wegama lomkhiqizo. Okwamanje ayitholakali ngendlela ejwayelekile.

I-Ilumya iqukethe isidakamizwa i-tildrakizumab, esibizwa nangokuthi i-tildrakizumab-asmn.

Izindleko ze-Ilumya

Njengayo yonke imithi, izindleko ze-Ilumya zingahluka.

Izindleko zakho zangempela zizoxhomeka kumshuwalense wakho.

Usizo lwezezimali nolomshuwalense

Uma udinga uxhaso lwezezimali ukukhokhela i-Ilumya, usizo luyatholakala.

ISun Pharma Global FZE, engumkhiqizi we-Ilumya, izohlinzeka ngohlelo olubizwa nge-Ilumya Support Lighting the Way. Ngeminye imininingwane, shayela ku-855-4ILUMYA (855-445-8692) noma uvakashele iwebhusayithi ye-Ilumya.

I-Ilumya isebenzisa

Ukuphathwa Kwezokudla Nezidakamizwa (i-FDA) kuvumela imishanguzo kadokotela efana ne-Ilumya ukwelapha izimo ezithile. I-Ilumya nayo ingasetshenziswa ngaphandle kwelebula ngezinye izimo.

I-Ilumya ye-plaque psoriasis

I-Ilumya igunyazwe yi-FDA ukwelapha i-plaque psoriasis elinganiselayo kuya kwabakhulu kubantu abadala abakulungele ukwelashwa kwesistimu noma i-phototherapy. Ukwelashwa okuhleliwe yimithi ethathwe ngomlomo noma ngomjovo futhi isebenza kuwo wonke umzimba. I-Phototherapy (ukwelashwa okulula) ukwelashwa okubandakanya ukuveza isikhumba esithintekile ekukhanyeni kwemvelo noma okufakelwayo kwe-ultraviolet.

Abantu abakulungele ukwelashwa kwesistimu noma i-phototherapy ngokuvamile yilabo:

• ube ne-plaque psoriasis elinganiselayo kuya kwelinzima, noma
• bazamile ukwelashwa ngezihloko kodwa bathola ukuthi lezi zindlela zokwelapha azizilawulanga izimpawu zabo ze-psoriasis

Ngokusho kweNational Psoriasis Foundation, i-plaque psoriasis ibhekwa njengelingene kuya kokubi uma amapuleti emboza ngaphezu kwamaphesenti amathathu womzimba wakho. Ukuqhathanisa, isandla sakho sonke sakha cishe iphesenti elilodwa lomzimba wakho.

Uma unamapuleti ezindaweni ezibucayi, njengezandla zakho, izinyawo, ubuso, noma izitho zangasese, i-psoriasis yakho nayo ibhekwa njengolinganiselayo kuya kokubi kakhulu.

Ukusetshenziswa okungavunyelwe

I-Ilumya ingasetshenziswa ngaphandle kwelebula ngezinye izimo. Ukusetshenziswa okungekho kwelebula kulapho kunqunywa umuthi ovunyelwe ukwelapha umbandela owodwa ukwelapha isimo esihlukile.

I-psoriatic arthritis

I-Ilumya ayivunyelwe ukwelapha i-psoriatic arthritis, kepha ingahle inqunyelwe ukuthi ayikho kwelebula yalesi simo. I-Psoriatic arthritis ifaka izimpawu ze-psoriasis yesikhumba kanye namalunga abuhlungu, avuvukile.

Kwesinye isifundo esincane somtholampilo, u-Ilumya akazange athuthukise kakhulu izimpawu ze-psoriatic arthritis noma ubuhlungu lapho esetshenziselwa amasonto ayi-16, uma kuqhathaniswa ne-placebo (akukho ukwelashwa).

Kodwa-ke, kwenziwa izifundo ezengeziwe zokuhlola ukuthi ngabe i-Ilumya iyasiza yini ekwelapheni i-psoriatic arthritis. Olunye ucwaningo lwesikhathi eside lomtholampilo luyaqhubeka njengamanje.

I-Ankylosing spondylitis

I-Ilumya ayivunyelwe ukwelashwa kwe-ankylosing spondylitis (i-arthritis ethinta umgogodla wakho). Kodwa-ke, kunesifundo esiqhubekayo somtholampilo sokuhlola ukuthi siyasebenza yini kulesi simo.

Isikali se-Ilumya

Imininingwane elandelayo ichaza isilinganiso esijwayelekile se-Ilumya. Kodwa-ke, qiniseka ukuthatha isilinganiso udokotela wakho akubekela sona. Udokotela wakho uzonquma isilinganiso esihle kakhulu ukuhlangabezana nezidingo zakho.

Amafomu wezidakamizwa namandla

U-Ilumya uza ngesirinji eyodwa egcwaliswe ngomthamo owodwa. Isirinji ngayinye iqukethe i-100 mg ye-tildrakizumab ku-1 ml yesisombululo.

I-Ilumya inikezwa njengomjovo ngaphansi kwesikhumba sakho (ngaphansi kwesikhumba).

Isikali se-plaque psoriasis

Umthamo onconyiwe we-Ilumya we-plaque psoriasis umjovo owodwa ongaphansi kuka-100-mg.

Uzothola imijovo yokuqala neyesibili ngokuhlukana amasonto amane. Ngemuva komthamo wesibili, uzothola yonke imithamo eyengeziwe njalo emavikini ayi-12. Umhlinzeki wezokunakekelwa kwempilo ehhovisi likadokotela wakho uzonika umjovo ngamunye.

Kuthiwani uma ngiphuthelwa umthamo?

Uma ukhohlwa ukuya ehhovisi likadokotela wakho ukuthola umthamo, shayela ukuhlela kabusha ukuqokwa kwakho ngokushesha nje lapho ukhumbula. Ngemuva kwalokho, qhubeka neshejuli ejwayelekile enconyiwe.

Isibonelo, uma usuvele uthole imithamo emibili yokuqala, ungahlelela umthamo olandelayo amasonto ayi-12 ngemuva kethamo lakho lokwenza.

Ngabe kuzodingeka ngisebenzise lesi sidakamizwa isikhathi eside?

Lokho kuzoncika ekutheni wena nodokotela wakho niyabona yini ukuthi i-Ilumya iphephile futhi iyasebenza ekwelapheni i-psoriasis yakho. Uma wenza kanjalo, ungasebenzisa umuthi isikhathi eside ukulawula izimpawu zakho ze-psoriasis.

Imiphumela emibi ye-Ilumya

I-Ilumya ingadala imiphumela emibi noma emibi. Uhlu olulandelayo luqukethe eminye yemiphumela emibi engaba khona ngenkathi uthatha i-Ilumya. Lolu hlu alubandakanyi yonke imiphumela emibi engaba khona.

Ngeminye imininingwane ngemiphumela engemihle ye-Ilumya noma amathiphu wokuthi ungabhekana kanjani nemiphumela emibi ekhathazayo, khuluma nodokotela wakho noma usokhemisi.

Imiphumela emibi ejwayelekile

Imiphumela emibi ejwayelekile ye-Ilumya ingafaka:

• izifo eziphezulu zokuphefumula
• ukuphendula kwesiza somjovo
• isifo sohudo

Iningi lalemiphumela emibi ingahle ihambe ezinsukwini ezimbalwa noma emasontweni ambalwa. Uma zinzima kakhulu noma zingahambi, khuluma nodokotela wakho noma usokhemisi.

Imiphumela emibi kakhulu

Imiphumela emibi ebucayi evela ku-Ilumya ayijwayelekile, kodwa ingenzeka. Shayela udokotela wakho ngokushesha uma unemiphumela emibi kakhulu. Shayela u-911 uma izimpawu zakho zizizwa zisongela impilo noma uma ucabanga ukuthi unezimo eziphuthumayo zezokwelapha.

Imiphumela emibi kakhulu ingafaka ukusabela okweqile ku-Ilumya. Izimpawu zifaka:

• ukuqubuka kwesikhumba
• ukulunywa
• ukuvuvukala komphimbo wakho, umlomo, noma ulimi, okungadala inkinga yokuphefumula
• i-angioedema (ukuvuvukala ngaphansi kwesikhumba sakho, imvamisa ezinkalweni zakho, izindebe, izandla, noma izinyawo)

Ukuphendula kwesayithi lokujova

Ezifundweni zomtholampilo, ukusabela kwendawo yokujova kwenzeka emaphesentini ama-3 wabantu abathola i-Ilumya. Izimpawu esizeni somjovo zingafaka:

• ububomvu
• isikhumba esilumayo
• ubuhlungu endaweni yomjovo
• ukulinyazwa
• ukuvuvukala
• ukuvuvukala
• ukopha

Ukuphendula kwesayithi lokujova ngokuvamile akunzima futhi kufanele kuphele zingakapheli izinsuku ezimbalwa. Uma zinzima noma zingahambi, khuluma nodokotela wakho.

Uhudo

Uhudo lwenzeke ngamaphesenti ama-2 wabantu abathola i-Ilumya ezifundweni zokwelashwa. Lo mphumela ohlangothini ungaphela ngokusetshenziswa okuqhubekayo komuthi. Uma uhudo lwakho lukhulu noma luhlala isikhathi eside kunezinsuku ezimbalwa, khuluma nodokotela wakho.

Ingozi eyengeziwe yokutheleleka

Ezifundweni zokwelashwa, amaphesenti angama-23 abantu abathola i-Ilumya bathole ukutheleleka. Kubalulekile ukuthi uqaphele, noma kunjalo, ukuthi inani elifanayo lokutheleleka lenzeke kubantu abathola i-placebo (akukho ukwelashwa).

Ukutheleleka okuvame kakhulu kubantu abathatha i-Ilumya kwakuyizifo eziphezulu zokuphefumula, njengomkhuhlane ojwayelekile. Kuze kube ngabantu abangamaphesenti ayi-14 ocwaningweni ababenegciwane lokuphefumula. Kodwa-ke, cishe zonke izifo zazincane noma zingathí sina. Amaphesenti angaphansi kuka-0,3 okutheleleka abhekwa njengobucayi.

I-Ilumya inyusa ubungozi bokutheleleka ngoba yehlisa ukusebenza kwezingxenye ezithile zamasosha akho omzimba. Amasosha omzimba wakho avikela umzimba wakho ekutheleleni.

Ngaphambi kokuba uqale ukwelashwa nge-Ilumya, udokotela wakho uzokuhlolela izifo, okubandakanya isifo sofuba (TB). Uma unomlando we-TB noma une-TB esebenzayo, kuzodingeka uthole ukwelashwa kwalesi simo ngaphambi kokuba uqale ukuthatha i-Ilumya.

Kukho konke ukwelashwa kwakho kwe-Ilumya, kubalulekile ukuxhumana nodokotela wakho ngokushesha uma unezimpawu ze-TB. Lokhu kufaka phakathi umkhuhlane, ubuhlungu bemisipha, ukwehla kwesisindo, ukukhwehlela, noma igazi ku-mucus yakho.

Ukusabela komzimba ku-Ilumya

Ezifundweni zomtholampilo, bangaphansi kwamaphesenti ayi-7 abantu abathatha i-Ilumya baba nokusabela lapho amasosha abo omzimba akha amasosha omzimba ku-Ilumya.

Ama-antibody amaphrotheni alwa nezinto zangaphandle emzimbeni wakho njengabahlaseli. Umzimba ungenza ama-antibody kunoma iyiphi into yangaphandle, kufaka phakathi ama-antibody monoclonal njenge-Ilumya.

Uma umzimba wakho uba nama-antibody ku-Ilumya, kungenzeka ukuthi umuthi ngeke usasebenza ekwelapheni i-psoriasis yakho. Kubalulekile ukuthi uqaphele, noma kunjalo, ukuthi i-Ilumya yenziwa yasebenza kancane kubantu abangamaphesenti ama-3 kuphela abayitholile.

Ezinye izindlela ze-Ilumya

Ezinye izidakamizwa ziyatholakala ezingelapha i-plaque psoriasis ngokulingene kuya kokulingene. Ezinye zingakulungela kangcono kunabanye. Uma unentshisekelo yokuthola enye indlela ye-Ilumya, khuluma nodokotela wakho ukuze ufunde kabanzi ngeminye imithi engakusebenzela kahle.

Izibonelo zezinye izidakamizwa ezingasetshenziswa ukwelapha i-plaque psoriasis elinganiselayo kuya kwezimbi zifaka:

• i-methotrexate (i-Otrexup, i-Rasuvo, i-Trexall)
• i-adalimumab (Humira)
• i-etanercept (Enbrel)
• secukinumab (Cosentyx)
• ustekinumab (Stelara)
• i-guselkumab (Tremfya)

Ilumya vs. Tremfya

Ungase uzibuze ukuthi i-Ilumya iqhathanisa kanjani neminye imithi enqunyelwe ukusetshenziswa okufanayo. Lapha sibheka ukuthi i-Ilumya neTremfya ziyefana futhi zehlukile kanjani.

Mayelana

I-Ilumya iqukethe i-tildrakizumab, okuwuhlobo lomuthi obizwa ngokuthi i-monoclonal antibody. I-Tildrakizumab ivimbela (ivimba) umsebenzi weprotheyini ebizwa nge-interleukin-23 (IL-23) molecule. Ku-plaque psoriasis, le molekyuli iyabandakanyeka ekwakhiweni kweseli lesikhumba okuholela emaphepheni.

I-Tremfya futhi i-anti-monoclonal antibody evimba umsebenzi we-IL-23. Iqukethe i-guselkumab yezidakamizwa.

I-Ilumya neTremfya zombili izidakamizwa ze-biologic ezinciphisa ukuvuvukala futhi zisize ukuvimbela ukwakheka kwamapuleti kubantu abane-psoriasis. I-Biologics yimithi eyenziwe ngezinto eziphilayo kunamakhemikhali.

Isebenzisa

I-Ilumya neTremfya bobabili bavunyelwe yi-FDA ukwelapha i-plaque psoriasis elinganiselayo kuya kwelinzima kubantu abadala abakulungele ukwelashwa kwesistimu noma i-phototherapy.

Ukwelashwa okuhleliwe kunemithi ethathwe ngomlomo noma ngemijovo esebenza kuwo wonke umzimba. I-Phototherapy ifaka ukuveza isikhumba esithintekile ekukhanyeni kwemvelo noma okufakelwayo kwe-ultraviolet.

Lezi zinhlobo zokwelashwa ngokuvamile zisetshenziselwa i-plaque psoriasis elinganiselayo noma enzima noma yabantu abangaphenduli ekwelashweni okuyisihloko (okusetshenziswa esikhumbeni).

Amafomu wezidakamizwa nokuphathwa

U-Ilumya uza ngesirinji ekhethwe ngomthamo owodwa equkethe u-100 mg we-tildrakizumab. I-Ilumya inikezwa njengomjovo ngaphansi kwesikhumba (ngaphansi kwesikhumba) ehhovisi likadokotela. Imijovo emibili yokuqala inikezwa amasonto amane ehlukene. Ngemuva kwaleyo mijovo, amanani anikezwa njalo emavikini ayi-12.

Njengo-Ilumya, iTremfya iza ngesirinji ekhethwe ngomthamo owodwa, kepha iqukethe i-100 mg ye-guselkumab. Iphinde inikezwe njengomjovo ongaphansi. Futhi njengo-Ilumya, imijovo emibili yokuqala inikezwa amasonto amane ngokuhlukana. Kodwa-ke, yonke imithamo ngemuva kwalokho inikezwa njalo emavikini ayisishiyagalombili.

I-Tremfya inganikezwa ehhovisi likadokotela wakho, noma uzijohele ekhaya ngemuva kokuthola ukuqeqeshwa okufanelekile kumhlinzeki wakho wezokunakekelwa kwempilo.

Imiphumela emibi kanye nezingozi

I-Ilumya neTremfya zinemiphumela emibi efanayo futhi ezinye zihlukile. Izibonelo zibalwe ngezansi.

Ukusebenza ngempumelelo

I-Ilumya neTremfya azizange ziqhathaniswe nezifundo zomtholampilo, kepha zombili ziyasebenza ekwelapheni i-plaque psoriasis elinganiselayo nelinzima.

Ukuqhathanisa okungaqondile kwemithi ye-plaque psoriasis kutholakale ukuthi iTremfya ingasebenza kangcono ekuthuthukiseni izimpawu kune-Ilumya. Kulolu cwaningo, abantu abathathe i-Tremfya babenamathuba aphindwe ka-12.4 okuba nokuthuthuka okungamaphesenti angama-75 ezimpawu, uma kuqhathaniswa nabantu abathathe i-placebo (abalashwa).

Kucwaningo olufanayo, abantu abathathe i-Ilumya babenamathuba aphindwe kayi-11 okuthola imiphumela efanayo uma kuqhathaniswa ne-placebo.

Izindleko

I-Ilumya neTremfya zombili izidakamizwa ezibizwa ngamagama. Okwamanje azikho izinhlobo ezijwayelekile zomuthi.Imithi enegama lomkhiqizo ivame ukubiza ngaphezu kwama-generic.

I-Ilumya neTremfya ngokuvamile zibiza ngokufana. Izindleko zangempela ozikhokhela noma yisiphi isidakamizwa zizoya ngohlelo lwakho lomshuwalense.

Ilumya vs. ezinye izidakamizwa

Ngaphezu kweTremfya, kunezinye izidakamizwa eziningana ezisetshenziselwa ukwelapha i-plaque psoriasis. Ngezansi ukuqhathanisa phakathi kwe-Ilumya neminye yale mithi.

Ilumya vs. Cosentyx

I-Ilumya iqukethe i-tildrakizumab, okuwuhlobo lomuthi obizwa ngokuthi i-monoclonal antibody. I-Tildrakizumab ivimbela (ivimba) umsebenzi weprotheyini ebizwa nge-interleukin-23 (IL-23) molecule. Ku-plaque psoriasis, le molekyuli iyabandakanyeka ekwakhiweni kweseli lesikhumba okuholela emaphepheni.

ICosentyx nayo iyi-antibody eyodwa. Iqukethe i-secukinumab yezidakamizwa futhi ivimba i-interleukin-17A (IL-17A). Njenge-IL-23, i-IL-17A ibandakanyeka ekwakhiweni kwamaseli esikhumba okuholela kuma-plaque.

Yize i-Ilumya neCosentyx kuyizidakamizwa ze-biologic zombili, zisebenza ngezindlela ezihluke kancane.

I-Biologics yimithi eyenziwe ngezinto eziphilayo kunamakhemikhali.

Isebenzisa

I-Ilumya neCosentyx zombili zivunyelwe i-FDA ukwelapha i-plaque psoriasis elinganiselayo kuya kwelinzima kubantu abadala abafuna ukwelashwa okuhleliwe noma i-phototherapy. Ukwelashwa okuhleliwe yimithi ethathwa ngomlomo noma ngomjovo futhi isebenza kuwo wonke umzimba. I-Phototherapy ifaka ukuveza isikhumba esithintekile ekukhanyeni kwe-ultraviolet.

ICosentyx nayo ivunyelwe yi-FDA ukwelapha i-psoriatic arthritis (i-psoriasis ene-arthritis ehlangene) ne-ankylosing spondylitis (isifo samathambo emgogodleni).

Amafomu wezidakamizwa nokuphathwa

I-Ilumya neCosentyx bobabili banikezwa njengemijovo ngaphansi kwesikhumba (ngaphansi kwesikhumba).

U-Ilumya unikezwa ehhovisi likadokotela ngumhlinzeki wezempilo. Imijovo emibili yokuqala inikezwa amasonto amane ehlukene. Ngemuva kwaleyo mijovo emibili, amanani anikezwa njalo emavikini ayi-12. Umthamo ngamunye ungu-100 mg.

Umthamo wokuqala weCosentyx uvame ukunikezwa ehhovisi likadokotela. Ngemuva kwalokho, umuthi ungazilimaza ekhaya ngemuva kokuqeqeshwa okufanele nomhlinzeki wezokunakekelwa kwempilo.

KwiCosentyx, imijovo emibili ye-150 mg (yenani eliphelele lama-300 mg umthamo ngamunye) inikezwa masonto onke amasonto amahlanu. Ngemuva kwalokho, umjovo owodwa unikezwa inyanga ngayinye. Elinye lale mithamo ngokujwayelekile liyi-300 mg, noma abanye abantu bengadinga kuphela i-150 mg ngomthamo ngamunye.

Imiphumela emibi kanye nezingozi

I-Ilumya neCosentyx zinemiphumela emibi efanayo futhi eminye yehlukile. Izibonelo zemiphumela emibi yazo zombili izidakamizwa zibalwe ngezansi.

Ukusebenza ngempumelelo

I-Ilumya neCosentyx azikaqhathaniswa ezifundweni zomtholampilo, kepha zombili ziyasebenza ekwelapheni i-plaque psoriasis elinganiselayo nelinzima.

Ukuqhathanisa okungaqondile kwemithi ye-plaque psoriasis kutholakale ukuthi iCosentyx ingasebenza kangcono kune-Ilumya ekuthuthukiseni izimpawu. Kulolu cwaningo, abantu abathathe ama-300 mg weCosentyx babenamathuba aphindwe ka-17.5 okuba nokuthuthuka okungamaphesenti angama-75 ezimpawu uma kuqhathaniswa nabantu abathathe i-placebo (alukho umuthi).

Kucwaningo olufanayo, abantu abathathe i-Ilumya babenamathuba aphindwe kayi-11 okuthola imiphumela efanayo, uma kuqhathaniswa ne-placebo.

Izindleko

I-Ilumya neCosentyx zombili izidakamizwa ezidla igama. Okwamanje awekho amafomu ejwayelekile atholakala kunoma imuphi umuthi. Imithi enegama lomkhiqizo ivame ukubiza ngaphezu kwama-generic.

I-Ilumya neCosentyx ngokuvamile kubiza cishe okufanayo. Izindleko zangempela ozikhokhela noma yisiphi isidakamizwa zizoya ngohlelo lwakho lomshuwalense.

Ilumya vs. Humira

I-Ilumya iqukethe i-tildrakizumab, okuwuhlobo lomuthi obizwa ngokuthi i-monoclonal antibody. I-Tildrakizumab ivimbela (ivimba) umsebenzi weprotheyini ebizwa nge-interleukin-23 (IL-23) molecule. Ku-plaque psoriasis, le molekyuli iyabandakanyeka ekwakhiweni kweseli lesikhumba okuholela emaphepheni.

I-Humira iqukethe isidakamizwa i-adalimumab. Futhi i-antibody monoclonal futhi ivimba ukusebenza kweprotheni ebizwa nge-tumor necrosis factor-alpha (TNF-alpha). I-TNF-alpha iyisithunywa samakhemikhali esidala ukukhula masinyane kwesikhumba esikhunjeni ku-plaque psoriasis.

Yize u-Ilumya noHumira beyizidakamizwa ze-biologic ezivimbela izinqubo zomzimba, zisebenza ngezindlela ezihlukile. I-Biologics yimithi eyenziwe ngezinto eziphilayo kunamakhemikhali.

Isebenzisa

U-Ilumya noHumira bobabili bavunyelwe yi-FDA ukwelapha i-plaque psoriasis elinganiselayo kuya kwelinzima kubantu abadala abafuna ukwelashwa okuhleliwe noma i-phototherapy. Ukwelashwa okuhleliwe yimithi ethathwa ngomlomo noma ngomjovo futhi isebenza kuwo wonke umzimba. I-Phototherapy ifaka ukwelapha isikhumba esithintekile ngokuvezwa kokukhanya kwe-ultraviolet.

I-Humira inokunye ukusetshenziswa okuvunyelwe yi-FDA, okunye okubandakanya:

• isifo samathambo
• isifo samathambo psoriatic
• Isifo sikaCrohn
• i-ankylosing spondylitis
• ukulunywa yizilonda emathunjini

Amafomu wezidakamizwa nokuphathwa

U-Ilumya noHumira bobabili banikezwa njengemijovo ngaphansi kwesikhumba (ngaphansi kwesikhumba).

U-Ilumya unikezwa ehhovisi likadokotela ngumhlinzeki wezempilo. Imijovo emibili yokuqala inikezwa amasonto amane ehlukene. Ngemuva kwaleyo mijovo emibili, amanani anikezwa njalo emavikini ayi-12. Umthamo ngamunye ungu-100 mg.

I-Humira iphinde inikezwe ehhovisi likadokotela, noma njenge-self-injection ekhaya ngemuva kokuqeqeshwa okufanelekile kumhlinzeki wezokunakekelwa kwempilo. Umthamo wokuqala ungama-80 mg, kulandele umthamo we-40-mg ngesonto elilodwa kamuva. Ngemuva kwalokho, umthamo we-40-mg unikezwa njalo emavikini amabili.

Imiphumela emibi kanye nezingozi

U-Ilumya noHumira basebenza ngezindlela ezingafani kodwa banemiphumela emibi efanayo. Izibonelo zemiphumela emibi ejwayelekile futhi emibi yomuthi ngamunye zibhalwe ngezansi.

UHumira unezixwayiso zesibhakela ezivela ku-FDA. Isixwayiso esibhoksi yilona hlobo oluqine kakhulu lwezexwayiso oludingwa yi-FDA. Izexwayiso zithi uHumira wandise ingozi yokutheleleka okunzima kanye nomdlavuza othile.

Ukusebenza ngempumelelo

U-Ilumya noHumira abakaze baqhathaniswe nezifundo zomtholampilo, kepha zombili ziyasebenza ekwelapheni i-plaque psoriasis elinganiselayo nelinzima.

Ukuqhathanisa okukodwa okungaqondile kuthola ukuthi u-Ilumya wasebenza mayelana noHumira njengokwelashwa kwe-plaque psoriasis. Kulolu cwaningo, abantu abathathe noma yisiphi isidakamizwa babenamathuba aphindwe kayishumi nanhlanu okuba nokuthuthuka kwezimpawu kunabantu abathathe i-placebo (abekho ukwelashwa).

Kodwa-ke, ngokususelwa ekuhlaziyweni kwayo kwezinye izidakamizwa, lolu cwaningo luphakamise ukuthi izidakamizwa eziqonde ku-IL-23, njenge-Ilumya, zibonakala zisebenza kakhulu ekwelapheni i-plaque psoriasis kunama-TNF-blockers, anjengeHumira. Kudingeka izifundo eziningi.

Izindleko

U-Ilumya noHumira bobabili izidakamizwa zomuthi. Okwamanje azikho izinhlobo ezijwayelekile zomuthi. Imithi enegama lomkhiqizo ivame ukubiza ngaphezu kwama-generic.

Kodwa-ke, kunezinhlobo eziningi ze-adalimumab (umuthi eHumira) ezivunyelwe ukwelapha i-psoriasis. Lokhu kufaka phakathi iHyrimoz, iCyltezo, ne-Amjevita. Izidakamizwa ze-Biosimilar ziyefana nomuthi we-biologic asuselwe kuwo, kodwa awazona izifaniso eziqondile. Izidakamizwa ze-biosimilar zingabiza cishe amaphesenti angama-30 ngaphansi komuthi wokuqala.

U-Ilumya noHumira ngokuvamile babiza cishe okufanayo. Izindleko zangempela ozikhokhela noma yisiphi isidakamizwa zizoya ngohlelo lwakho lomshuwalense.

Ilumya vs. Enbrel

I-Ilumya iqukethe i-tildrakizumab, okuwuhlobo lomuthi obizwa ngokuthi i-monoclonal antibody. I-Tildrakizumab ivimbela (ivimba) umsebenzi weprotheyini ebizwa nge-interleukin-23 (IL-23) molecule. Ku-plaque psoriasis, le molekyuli iyabandakanyeka ekwakhiweni kweseli lesikhumba okuholela emaphepheni.

I-Enbrel nayo iyi-antibody e-monoclonal. Iqukethe i-etanercept yezidakamizwa, evimba ukusebenza kweprotheni ebizwa nge-tumor necrosis factor-alpha (TNF-alpha). I-TNF-alpha iyisithunywa samakhemikhali esidala ukukhula masinyane kwesikhumba esikhunjeni ku-plaque psoriasis.

Kokubili i-Ilumya ne-Enbrel yizidakamizwa ze-biologic ezinciphisa ukwakheka kwamapuleti, kepha zikwenza ngezindlela ezihlukile. I-Biologics yimithi eyenziwe ngezinto eziphilayo kunamakhemikhali.

Isebenzisa

I-Ilumya ne-Enbrel bobabili bavunyelwe yi-FDA ukwelapha i-plaque psoriasis elinganiselayo kuya kwelinzima kubantu abadala abafuna ukwelashwa okuyi-systemic noma i-phototherapy. Ukwelashwa okuhleliwe yimithi ethathwa ngomlomo noma ngomjovo futhi isebenza kuwo wonke umzimba. I-Phototherapy ifaka ukwelapha isikhumba esithintekile ngokuvezwa kokukhanya kwe-ultraviolet.

I-Enbrel nayo ivunyelwe ukwelapha i-plaque psoriasis elinganiselayo kuya kwelinamandla ezinganeni ezineminyaka engama-4 nangaphezulu, kanye ne:

• isifo samathambo
• i-polyarticular juvenile idiopathic arthritis
• isifo samathambo psoriatic
• i-ankylosing spondylitis

Amafomu wezidakamizwa nokuphathwa

I-Ilumya ne-Enbrel bobabili banikezwa njengemijovo ngaphansi kwesikhumba (ngaphansi kwesikhumba).

U-Ilumya uza ngesirinji eyodwa egcwaliswe ngomthamo owodwa. Inikezwa ehhovisi likadokotela ngumhlinzeki wakho wezokunakekelwa kwempilo. Imijovo emibili yokuqala inikezwa amasonto amane ehlukene. Ngemuva kwaleyo mijovo emibili, amanani anikezwa njalo emavikini ayi-12. Umjovo ngamunye ngu-100 mg.

I-Enbrel iphinde inikezwe ehhovisi likadokotela noma njenge-self-injection ekhaya ngemuva kokuqeqeshwa okufanele kusuka kumhlinzeki wezokunakekelwa kwempilo. Ezinyangeni ezintathu zokuqala, u-Enbrel unikezwa kabili ngesonto. Ngemuva kwalokho, umthamo wesondlo unikezwa kanye ngesonto. Umthamo ngamunye ungama-50 mg.

I-Enbrel itholakala ngezinhlobo eziningi, kufaka phakathi isiponji esenziwe ngomthamo owodwa kanye ne-autoinjector.

Imiphumela emibi kanye nezingozi

U-Ilumya no-Enbrel basebenza ngezindlela ezahlukahlukene kepha banemiphumela efanayo efanayo. Izibonelo zemiphumela emibi ejwayelekile futhi emibi yomuthi ngamunye zibhalwe ngezansi.

U-Enbrel unezixwayiso zesibhakela ezivela ku-FDA. Isixwayiso esibhoksi yilona hlobo oluqine kakhulu lwezexwayiso oludingwa yi-FDA. Izexwayiso zithi i-Enbrel yandisa ubungozi bokutheleleka okunzima kanye nomdlavuza othile.

Ukusebenza ngempumelelo

U-Ilumya no-Enbrel bobabili bayasebenza ekwelapheni i-plaque psoriasis, kepha i-Ilumya ingasebenza kakhulu ekwehliseni izimpawu zoqwembe.

Kokunye ukuhlola komtholampilo, amaphesenti angama-61 abantu abathola i-Ilumya babenokuthuthuka kwezimpawu okungenani kwamaphesenti angama-75. Ngakolunye uhlangothi, amaphesenti angama-48 abantu abathola i-Enbrel babe nokuthuthuka okufanayo.

Izindleko

I-Ilumya ne-Enbrel zombili izidakamizwa ezidla igama. Okwamanje azikho izinhlobo ezijwayelekile zomuthi. Imithi enegama lomkhiqizo ivame ukubiza ngaphezu kwama-generic.

I-Enbrel ibiza kancane kune-Ilumya. Izindleko zangempela ozikhokhela noma yisiphi isidakamizwa zizoya ngohlelo lwakho lomshuwalense.

Ilumya vs. methotrexate

I-Ilumya iqukethe i-tildrakizumab, okuwuhlobo lomuthi obizwa ngokuthi i-monoclonal antibody. I-Tildrakizumab ivimbela (ivimba) umsebenzi weprotheyini ebizwa nge-interleukin-23 (IL-23) molecule. Le molekyuli ibandakanyeka ekwakhiweni kwamangqamuzana esikhumba okuholela emaphepheni.

I-Methotrexate (i-Otrexup, i-Trexall, i-Rasuvo) uhlobo lomuthi obizwa nge-antimetabolite, noma i-folic acid antagonist (blocker). IMethotrexate isebenza ngokuvimba umsebenzi we-enzyme ebandakanyeka ekukhuleni kwamangqamuzana esikhumba nokwakhiwa kwamacwecwe.

I-Ilumya yisidakamizwa se-biologic, kanti i-methotrexate iyindlela ejwayelekile yokwelapha. Ukwelashwa okuhleliwe kubhekisa kuzidakamizwa ezithathwa ngomlomo noma ngomjovo futhi zisebenza kuwo wonke umzimba. I-Biologics yimithi eyenziwe ngezinto eziphilayo kunamakhemikhali.

Zombili lezi zidakamizwa zisiza ukuthuthukisa izimpawu ze-psoriasis ngokunciphisa ukwakheka koqwembe.

Isebenzisa

I-Ilumya ne-methotrexate zombili zivunyelwe i-FDA ukwelapha i-plaque psoriasis enzima. I-Ilumya nayo ivunyelwe ukwelapha i-plaque psoriasis elinganiselayo. I-Methotrexate yenzelwe ukuthi isetshenziswe kuphela lapho izimpawu zomuntu ze-psoriasis zinzima noma zikhubaza futhi zingaphenduli kweminye imithi.

IMethotrexate nayo ivunyelwe ukwelapha izinhlobo ezithile zomdlavuza kanye nesifo samathambo.

Amafomu wezidakamizwa nokuphathwa

I-Ilumya inikezwa njengomjovo ngaphansi kwesikhumba (ngaphansi kwesikhumba) ehhovisi likadokotela ngumhlinzeki wezokunakekelwa kwempilo. Imijovo emibili yokuqala inikezwa amasonto amane ehlukene. Ngemuva kwaleyo mijovo, amanani anikezwa njalo emavikini ayi-12. Umjovo ngamunye ngu-100 mg.

IMethotrexate iza njengethebhulethi yomlomo, isixazululo soketshezi, noma umjovo. Ekwelapheni i-plaque psoriasis, imvamisa kuthathwa ngomlomo. Kungathathwa njengomthamo owodwa kanye ngesonto, noma njengamanani amathathu anikezwe amahora ayi-12 ahlukene kanye ngesonto.

Imiphumela emibi kanye nezingozi

I-Ilumya ne-methotrexate kubangela imiphumela emibi eyejwayelekile ejwayelekile futhi emibi. Imiphumela emibi kakhulu futhi emibi kakhulu ebonwa kubantu abane-psoriasis ibalwe ngezansi. Lolu hlu alubandakanyi yonke imiphumela emibi engaba khona yomuthi.

IMethotrexate inezixwayiso eziningana ezisemabhokisini ezivela ku-FDA ezichaza ubungozi bomunye nomunye wemiphumela emibi ekhonjiswe ngenhla. Isexwayiso esibhakeleni yisixwayiso esiqine kakhulu esidingwa yi-FDA. Kwazisa odokotela neziguli ngemiphumela yezidakamizwa engaba yingozi.

Ukusebenza ngempumelelo

I-Ilumya ne-methotrexate azizange ziqhathaniswe ngqo ezifundweni zokwelashwa, kodwa zombili ziyasebenza ekwelapheni i-plaque psoriasis.

Ukuqhathanisa okukodwa okungaqondile kuthola ukuthi i-Ilumya isebenze cishe kanye ne-methotrexate ekwenzeni ngcono izimpawu ze-plaque psoriasis. Kodwa-ke, i-methotrexate kungenzeka ukuthi idale imiphumela emibi kakhulu uma iqhathaniswa ne-Ilumya.

Izindleko

I-Ilumya itholakala kuphela njengesidakamizwa esinegama lomkhiqizo. Okwamanje azikho izinhlobo ezijwayelekile ze-Ilumya. IMethotrexate iyatholakala njengesidakamizwa esijwayelekile kanye nemithi enegama iTrexall, iOtrexup, neRasuvo. Imithi enegama lomkhiqizo ivame ukubiza ngaphezu kwama-generic.

I-Ilumya ibiza ngaphezu kwamafomu ajwayelekile namagama e-methotrexate. Izindleko zangempela ozikhokhela noma yiziphi izinhlobo zomuthi othile zizoya ngohlelo lwakho lomshuwalense.

Ukusetshenziswa kwe-Ilumya nezinye izidakamizwa

I-Ilumya iyasebenza ekuthuthukiseni i-plaque psoriasis yodwa, kepha futhi ingasetshenziswa neminye imithi ngenzuzo eyengeziwe. Ukusebenzisa izindlela ezingaphezu kweyodwa ukwelapha i-psoriasis kungasiza ukusula amapuleti ngokushesha futhi kusule amaphesenti amakhulu wamapuleti.

Ukwelashwa kokuhlanganiswa kunganciphisa nomthamo owudingayo weminye imithi ye-psoriasis, eyehlisa ubungozi bemiphumela emibi. Ngaphezu kwalokho, ukwelashwa okuhlanganisiwe kunganciphisa ubungozi bokumelana ne-Ilumya (lapho umuthi ungasakusebenzeli).

Izibonelo zezinye izindlela zokwelapha ezingasetshenziswa ngokuphepha ne-Ilumya zifaka:

• ama-corticosteroids ama-topical, njenge-betamethasone
• okhilimu kanye nama-ointments (njenge-Dovonex ne-Vectical)
• i-methotrexate (i-Trexall, i-Otrexup, ne-Rasuvo)
• i-phototherapy (ukwelashwa okulula)

Ilumya notshwala

Akukho ukuxhumana okwaziwayo phakathi kotshwala ne-Ilumya ngalesi sikhathi. Kodwa-ke, isifo sohudo singumphumela oseceleni we-Ilumya kwabanye abantu. Ukuphuza utshwala nakho kungadala isifo sohudo. Ngakho-ke, ukuphuza utshwala ngenkathi uthola ukwelashwa kwe-Ilumya kungakhuphula ubungozi bakho balo mphumela wecala.

Utshwala bungenza futhi ukuthi ukwelashwa kwakho kwe-Ilumya kungasebenzi kahle. Lokhu kungenxa yemiphumela yotshwala ku-psoriasis uqobo, kanye nemiphumela yayo engaba khona ekutheni ulandela kanjani uhlelo lwakho lokwelashwa. Ukusetshenziswa kotshwala kunga:

• ukwandisa ukuvuvukala okungaholela ekwakhiweni kwamaseli esikhumba
• nciphisa amandla omzimba wakho wokulwa nezifo nezinkinga zesikhumba
• kukwenze ukhohlwe ukuthatha imishanguzo yakho noma ukuyeka ukulandela uhlelo lwakho lokwelashwa

Uma uthatha i-Ilumya futhi unenkinga yokugwema utshwala, khuluma nodokotela wakho ngezindlela zokuvimbela ukutheleleka nokwenza ngcono amathuba akho okwelashwa okuphumelelayo nge-Ilumya.

Ukusebenzisana kwe-Ilumya

U-Ilumya unokuxhumana okumbalwa kwezidakamizwa. Lokhu kungenxa yokuthi i-Ilumya namanye ama-antibody monoclonal ahlanganiswe ngomzimba, noma aphulwe, ngumzimba ngendlela ehlukile kunaleyo enezidakamizwa eziningi. (Ama-antibody eMonoclonal yizidakamizwa ezakhiwe ebhodini kusuka kumaseli omzimba.)

Izidakamizwa eziningi, amakhambi, nezithasiselo zenziwa ngama-enzyme esibindi sakho. I-Ilumya, ngakolunye uhlangothi, ihlanganiswa ngendlela efanayo namaseli omzimba avela kanye namaprotheni emzimbeni. Ngamafuphi, iphukile ngaphakathi kwamaseli emzimbeni wakho wonke. Ngoba i-Ilumya ayiphuli esibindini sakho nezinye izidakamizwa, ngokuvamile ayihlangani nazo.

Ilumya nemithi yokugoma ebukhoma

Ukuxhumana okubalulekile kwe-Ilumya yimithi yokugoma ebukhoma. Imishanguzo ebukhoma kufanele igwenywe ngesikhathi sokwelashwa nge-Ilumya.

Imishanguzo ebukhoma iqukethe inani elincane lamagciwane abuthaka. Ngenxa yokuthi i-Ilumya ivimba impendulo ejwayelekile yokulwa nezifo yomzimba wakho, umzimba wakho kungenzeka ungakwazi ukulwa negciwane emuthini wokugoma ophilayo ngenkathi uthatha umuthi.

Izibonelo zemithi yokugoma ebukhoma okufanele uyigweme ngesikhathi sokwelashwa kwe-Ilumya ifaka imigomo ye:

• isimungumungwane, imvukuzane, ne-rubella (MMR)
• ingxibongo
• i-yellow fever
• inqubulunjwana
• i-rotavirus

Ngaphambi kokuba uqale ukwelashwa nge-Ilumya, khuluma nodokotela wakho mayelana nokuthi ungadinga yini omunye wale mithi yokugoma. Wena nodokotela wakho ninganquma ukubambezela ukwelashwa no-Ilumya kuze kube yilapho senigonywe nganoma yimiphi imigomo ebukhoma eningayidinga.

Ungayithatha kanjani i-Ilumya

I-Ilumya inikezwa njengomjovo ngaphansi kwesikhumba (ngaphansi kwesikhumba) ngumhlinzeki wezokunakekelwa kwempilo ehhovisi likadokotela. Ufakwe esiswini sakho, emathangeni, noma ezingalweni ezingaphezulu. Imijovo esiswini sakho kufanele okungenani ibe ngamasentimitha ama-2 ukusuka kunkinobho yakho yesisu.

I-Ilumya akufanele ijovwe ezindaweni ezinesibazi, ama-stretch marks, noma imithambo yegazi. Akufanele futhi ifakwe emacwecweni, imihuzuko, noma ezindaweni ezibomvu noma zamathenda.

Ngaphambi kokuqala ukwelashwa kwe-Ilumya

Ngenxa yokuthi u-Ilumya wenza amasosha akho omzimba abe buthakathaka, udokotela wakho uzokuhlolela isifo sofuba (i-TB) ngaphambi kokuba uqale ukwelashwa. Uma une-TB esebenzayo, uzothola ukwelashwa kwe-TB ngaphambi kokuqala i-Ilumya. Futhi uma ubene-TB esikhathini esedlule, kungadingeka ukuthi welashwe ngaphambi kokuqala i-Ilumya.

Kodwa noma ungenazo izimpawu ze-TB, ungaba nohlobo olungasebenzi lwe-TB, olubizwa nge-TB efihlekile. Uma une-TB equbisile futhi uphuza i-Ilumya, i-TB yakho ingaqala ukusebenza. Uma ukuhlolwa kukhombisa ukuthi une-TB equbisile, kuzodingeka ukuthi uthole ukwelashwa kwe-TB ngaphambi noma ngesikhathi sokwelashwa kwakho ne-Ilumya.

Isikhathi

Umjovo wokuqala nowesibili we-Ilumya unikezwa amasonto amane ahlukene. Ngemuva kwale mithamo emibili yokuqala, uzobuyela ehhovisi likadokotela njalo emavikini ayi-12 ngomunye umthamo. Uma uphuthelwa i-aphoyintimenti noma umthamo, yenza enye i-aphoyintimenti ngokushesha okukhulu.

Usebenza kanjani u-Ilumya

I-plaque psoriasis yisifo sokuzilimaza komzimba, okuyisimo esidala ukuthi amasosha omzimba asebenze ngokweqile. I-plaque psoriasis ibangela amangqamuzana amhlophe egazi, asiza umzimba ukulwa nezifo, ukuthi ahlasele ngephutha amaseli omuntu uqobo. Lokhu kubangela ukuthi amangqamuzana esikhumba ahlukane ngokushesha futhi akhule.

Amaseli esikhumba akhiqizwa ngokushesha okukhulu kangangokuthi amangqamuzana amadala awanaso isikhathi sokuwa futhi enze indawo yamaseli amasha. Lokhu kukhiqizwa ngokweqile nokwakhiwa kwamangqamuzana esikhumba kubanga izindawo ezivuthayo, ezinamaxolo, ezibuhlungu zesikhumba ezibizwa ngokuthi izingcwecwe.

I-Ilumya i-antibody e-monoclonal, okuwuhlobo lomuthi owenziwe ngamaseli omzimba aselebhu. Ama-antibody e-monoclonal akhomba izingxenye ezithile zesistimu yomzimba.

U-Ilumya uvimba isenzo sephrotheni lomzimba elibizwa nge-interleukin-23 (IL-23). Nge-plaque psoriasis, i-IL-23 isebenzisa amakhemikhali abangela ukuthi amasosha omzimba ahlasele amangqamuzana esikhumba. Ngokuvimba i-IL-23, i-Ilumya isiza ukunciphisa ukwakheka kwamangqamuzana esikhumba namabala.

Ngoba i-Ilumya ivimba umsebenzi we-IL-23, ibizwa nge-interleukin inhibitor.

Kuthatha isikhathi esingakanani ukusebenza?

U-Ilumya uzoqala ukusebenza ngokushesha nje lapho uqala ukuwuthatha. Kodwa-ke, kuthatha isikhathi ukwakha ohlelweni lwakho futhi kusebenze ngokugcwele, ngakho-ke kungathatha amasonto ambalwa ngaphambi kokuthi ubone imiphumela.

Ezifundweni zokwelashwa, ngemuva kwesonto elilodwa lokwelashwa, bangaphansi kwamaphesenti angama-20 abantu abathatha i-Ilumya babona ukuthuthuka kwamapuleti. Kodwa-ke, ngemuva kwamasonto ayi-12, abantu abangaphezu kwesigamu abathola i-Ilumya babone intuthuko enkulu ezimpawu zabo ze-psoriasis. Inani labantu abanezimpawu ezithuthukisiwe liqhubeke nokukhula ngamasonto angama-28 okwelashwa.

Ilumya nokukhulelwa

Akwaziwa ukuthi i-Ilumya iphephile ukusetshenziswa ngesikhathi sokukhulelwa. Izifundo zezilwane zikhombise ingozi ethile embungwini lapho i-Ilumya inikezwa owesifazane okhulelwe. Kodwa-ke, izifundo zezilwane azihlali zibikezela ukuthi kuzokwenzekani ngabantu.

Uma ukhulelwe noma uhlela ukukhulelwa, khuluma nodokotela wakho ngezinzuzo nezingozi zokwelashwa kwe-Ilumya ngesikhathi sokukhulelwa.

Ilumya nokuncelisa

Akwaziwa ukuthi i-Ilumya idlulela ebisini lwebele lomuntu. Ezifundweni zezilwane, u-Ilumya wadlulela ebisini lwebele, edalula ukuncelisa ibele emuthini. Kodwa-ke, izifundo zezilwane azihlali zibikezela ukuthi kuzokwenzekani kubantu.

Uma ucabanga ukwelashwa kwe-Ilumya ngenkathi uncelisa, khuluma nodokotela wakho ngezinzuzo nezingozi.

Imibuzo ejwayelekile mayelana ne-Ilumya

Nazi izimpendulo zemibuzo ebuzwa njalo mayelana ne-Ilumya.

Ingabe i-Ilumya yelapha i-plaque psoriasis?

Cha, i-Ilumya ayilaphi i-plaque psoriasis. Okwamanje alikho ikhambi lalesi sifo. Kodwa-ke, ukwelashwa nge-Ilumya kungasiza ekuthuthukiseni izimpawu zakho ze-psoriasis.

Bengihlala ngisebenzisa okhilimu be-plaque psoriasis yami. Kungani ngidinga ukuqala ukuthola imijovo?

Udokotela wakho kungenzeka anqume ukuthi ukwelashwa okuhlelekile kungenza okuningi ukukhulula izimpawu zakho kunokhilimu bakho. Izidakamizwa zesistimu zinikezwa ngomjovo noma zithathwe ngomlomo futhi zisebenza kuwo wonke umzimba.

Imithi yokwelapha efana ne-Ilumya ngokuvamile iyasebenza kakhulu ekuthuthukiseni izimpawu ze-psoriasis kunezokwelapha (izidakamizwa ezisetshenziswa esikhumbeni). Lokhu kungenxa yokuthi basebenza ngaphakathi nangaphandle. Bakhomba amasosha omzimba uqobo, abangela amapuleti akho e-psoriasis. Lokhu kungasiza kokubili ukusula nokuvikela amapuleti e-psoriasis.

Ukwelashwa kwezihloko, ngakolunye uhlangothi, kuvamise ukuphatha amapuleti ngemuva kokuba sekwakhiwe.

Imithi yokwelashwa kwesinye isikhathi isetshenziswa ngokuhlanganiswa, noma esikhundleni sezinqubo zokwelashwa. Zingasetshenziswa uma:

• imishanguzo yezihloko ayizithuthukisi ngokwanele izimpawu zakho ze-plaque psoriasis, noma
• izingcwecwe zimboza ingxenye enkulu yesikhumba sakho (ngokuvamile amaphesenti ama-3 noma ngaphezulu), okwenza ukwelashwa ngezihloko ezithile kungasebenzi. Lokhu kubhekwa njenge-psoriasis elinganiselayo.

Ngizodinga isikhathi esingakanani ukuthatha i-Ilumya?

Ungathatha i-Ilumya isikhathi eside uma wena nodokotela wakho ninquma ukuthi i-Ilumya iphephile futhi iyasebenza kuwe.

Yini umuthi we-biologic?

Isidakamizwa se-biologic ngumuthi owenziwe kusuka kumaprotheni womuntu noma wezilwane. Izidakamizwa ze-biologic ezisetshenziselwa ukwelapha izifo ezizimele, njenge-plaque psoriasis, zisebenza ngokusebenzisana namasosha omzimba. Benza lokhu ngezindlela ezihlosiwe zokunciphisa ukuvuvukala nezinye izimpawu zesistimu yomzimba engasebenzi ngokweqile.

Ngenxa yokuthi zisebenzisana namaseli namasosha omzimba akhethekile kakhulu, i-biologics kucatshangwa ukuthi inemiphumela emibi embalwa uma iqhathaniswa nezidakamizwa ezithinta uhla olubanzi lwezinhlelo zomzimba, njengoba kwenza izidakamizwa eziningi.

Lapho isetshenziselwa ukwelapha i-psoriasis, imishanguzo ye-biologic ijwayele ukusetshenziselwa abantu abane-plaque psoriasis elinganiselayo nelinzima abangaphenduli kwezinye izindlela zokwelapha (njengokwelashwa ngezihloko).

Ngabe i-Ilumya isetshenziselwa ukwelapha i-psoriatic arthritis?

I-Ilumya ayivunyelwe yi-FDA ukwelapha i-psoriatic arthritis, kepha ingasetshenziswa ngaphandle kwelebula ngaleyo njongo.

Kwesinye isifundo esincane somtholampilo, u-Ilumya akazange athuthukise kakhulu izimpawu ze-psoriatic arthritis noma ubuhlungu, kodwa kwenziwa izifundo ezengeziwe zokuhlola ukuthi ngabe ziyasiza yini kulesi simo. Olunye ucwaningo lwesikhathi eside lomtholampilo luyaqhubeka njengamanje.

Kungani ngidinga ukuhlolwa i-TB ngaphambi kokuqala ukwelashwa no-Ilumya?

Udokotela wakho uzokuhlolela isifo sofuba esisebenzayo noma esifihlekile ngaphambi kokuba uqale ukwelashwa nge-Ilumya. Abantu abane-TB equbisile kungenzeka bangazi ukuthi banegciwane ngoba kaningi azikho izimpawu. Ukuhlolwa kwegazi ukuphela kwendlela yokwazi ukuthi umuntu one-TB equbisile uthelelekile yini.

Ukuhlolela i-TB ngaphambi kokwelashwa nge-Ilumya kubalulekile ngoba u-Ilumya wenza amasosha omzimba abe buthakathaka. Lapho amasosha omzimba ebuthakathaka, awakwazi ukulwa nezifo, futhi i-TB efihlekile ingasebenza. Izimpawu ze-TB esebenzayo zifaka phakathi umkhuhlane, ukukhathala, ukwehla kwesisindo, ukukhwehlela igazi, nobuhlungu besifuba.

Uma kutholakala ukuthi une-TB, kuzodingeka ukuthi uthole ukwelashwa kwe-TB ngaphambi kokuqala i-Ilumya.

Yini engingayenza ukuvimbela izifo ngenkathi ngithatha i-Ilumya?

Ukwelashwa kwe-Ilumya kwenza amasosha akho omzimba abe buthakathaka futhi kwandise amathuba okutheleleka. Izibonelo zokutheleleka okunjalo zifaka phakathi isifo sofuba, usiba, ukutheleleka kwefungal, kanye nezifo zokuphefumula.

Kodwa-ke, kunezinto eziningana ongazenza ukusiza ukuvikela izifo:

• Hlala usesikhathini ngemigomo, kufaka phakathi umkhuhlane (umkhuhlane).
• Gwema ukubhema.
• Geza izandla zakho ngensipho kaningi.
• Landela ukudla okunempilo.
• Lala ngokwanele.
• Gwema ukuba phakathi kwabantu abagulayo, uma kungenzeka.

Isexwayiso se-Ilumya

Ngaphambi kokuthatha u-Ilumya, khuluma nodokotela wakho ngomlando wakho wezempilo. I-Ilumya ingahle ingakulungeli uma unezimo ezithile zezokwelapha. Lokhu kufaka phakathi:

• Umlando wokusabela okukhulu kwe-hypersensitivity ku-Ilumya noma yiziphi izithako zawo. Uma uke wasabela kanzima ku-Ilumya esikhathini esedlule, akufanele uthole ukwelashwa ngalo muthi. Ukusabela okunzima kufaka ukuvuvukala kobuso noma kolimi nenkinga yokuphefumula.
• Ukutheleleka okusebenzayo noma umlando wezifo eziphindaphindwayo. I-Ilumya akufanele iqalwe ngabantu abanesifo samanje noma umlando wokutheleleka okuphindaphindiwe. Uma uba nokutheleleka ngenkathi uthatha i-Ilumya, tshela udokotela wakho khona manjalo. Bazokuqapha eduze futhi bangahle banqume ukumisa imishanguzo yakho ye-Ilumya kuze kutholakale ukutheleleka.
• Isifo sofuba. Uma une-TB equbisile noma i-TB esebenzayo, ungadinga ukwelashwa kwe-TB ngaphambi kokuqala i-Ilumya. Akufanele uqale i-Ilumya uma une-TB esebenzayo. (Uma une-TB equbisile, udokotela wakho angakwenza ukuthi uqale ukuphuza i-Ilumya ngenkathi welashwa i-TB.)

Imininingwane yobungcweti ye-Ilumya

Imininingwane elandelayo inikezwa odokotela nabanye ochwepheshe bezempilo.

Indlela yokusebenza

I-Ilumya iqukethe i-humanized monoclonal antibody tildrakizumab. Ibopha i-p19 subunit ye-interleukin-23 (IL-23) cytokine futhi iyivimbele ekubopheni kumamukeli we-IL-23. Ukuvimba umsebenzi we-IL-23 kuvimbela ukwenziwa kwendlela ye-T-helper cell 17 (Th17) enamandla.

I-Pharmacokinetics ne-metabolism

Ukutholakala okuphelele kwe-bioavailability kufinyelela kumaphesenti angama-80 kulandela umjovo ongaphansi. Ukuhlushwa okuphezulu kufinyelelwa ezinsukwini eziyisithupha. Ukuhlalwa kwesimo sokuqina kufinyelelwa ngeviki le-16.

I-Ilumya yehliselwa kuma-peptide amancane nama-amino acid nge-catabolism. Ukuqeda isigamu sempilo cishe izinsuku ezingama-23.

Izimo

I-Ilumya iyaphikiswa ezigulini ezinomlando wokusabela okukhulu kwe-hypersensitivity kumuthi noma kunoma yikuphi okokusebenzisa.

Imigomo

Gwema imigomo ebukhoma ezigulini ezithola i-Ilumya.

Ukuzilungiselela ngaphambili

Zonke iziguli kufanele zihlolwe ngesifo sofuba esifihlekile noma esisebenzayo ngaphambi kokwelashwa nge-Ilumya. Ungayiniki i-Ilumya iziguli ezine-TB esebenzayo. Iziguli ezine-TB equbisile kufanele ziqale ukwelashwa kwe-TB ngaphambi kokuqala ukwelashwa nge-Ilumya.

Isitoreji

I-Ilumya kufanele igcinwe esiqandisini ku-36⁰F kuye ku-46⁰F (2⁰C kuye ku-8⁰C). Gcina esitsheni sokuqala ukuvikela ekukhanyeni. I-Ilumya ingagcinwa ekamelweni lokushisa - kuze kufike ku-77⁰F (25⁰C) - kuze kube yizinsuku ezingama-30. Uma usugcinwe ekamelweni lokushisa, ungabuyeli esiqandisini. Ungafrizi noma unyakazise. Vumela u-Ilumya ahlale ekamelweni lokushisa imizuzu engama-30 ngaphambi kokuphathwa.

UkuzikhululaI-MedicalNewsToday yenze yonke imizamo yokuqinisekisa ukuthi lonke ulwazi luyiqiniso, luphelele futhi lusesikhathini. Kodwa-ke, le ndatshana akufanele isetshenziswe njengokungena esikhundleni solwazi nobungoti bochwepheshe bezokunakekelwa kwezempilo onelayisense. Kufanele uhlale uthintana nodokotela wakho noma omunye uchwepheshe wezokunakekelwa kwempilo ngaphambi kokuthatha noma imuphi umuthi. Imininingwane yezidakamizwa equkethwe lapha ingashintsha futhi ayihloselwe ukumboza konke ukusetshenziswa okungaba khona, izinkomba, izixwayiso, izexwayiso, ukuxhumana kwezidakamizwa, ukungezwani komzimba, noma imiphumela emibi. Ukungabikho kwezixwayiso noma olunye ulwazi lomuthi othile awukhombisi ukuthi inhlanganisela yezidakamizwa noma yezidakamizwa iphephile, iyasebenza, noma ilungele zonke iziguli noma konke ukusetshenziswa okuthile.